Eli Lilly and Co. (LLY) reported a profit for the first quarter of 2021 that declined 7 percent from last year, hurt by lower operating income, partially offset by higher other income and lower income tax expense. But quarterly revenue increased 16 percent. The company reported worldwide revenue of $810.1 million in the latest-quarter for its COVID-19 antibodies.
In Tuesday pre-market trade, LLY was trading at $180.49 down $6.73 or 3.59 percent.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com